Deciphering glycomics and neuroproteomic alterations in experimental traumatic brain injury: Comparative analysis of aspirin and clopidogrel treatment. Issue 11 (29th March 2016)

• Record Type: Journal Article
• Authors: Abou‐Abbass, Hussein; Bahmad, Hisham; Abou‐El‐Hassan, Hadi; Zhu, Rui; Zhou, Shiyue; Dong, Xue; Hamade, Eva; Mallah, Khalil; Zebian, Abir; Ramadan, Naify; Mondello, Stefania; Fares, Jawad; Comair, Youssef; Atweh, Samir; Darwish, Hala; Zibara, Kazem; Mechref, Yehia; Kobeissy, Firas
• Other Names: Mechref Yehia guestEditor.
• Is Part Of: Electrophoresis. Volume 37:Issue 11(2016)
• Page Start: 1562
• Page End: 1576
• Publication Date: 2016-03-29
• Subjects: Aspirin -- Clopidogrel -- Neuroproteomics -- PTMs -- TBI; Electrophoresis -- Periodicals; Electrophoresis -- Periodicals; 541.372
• DOI: 10.1002/elps.201500583
• Languages: English
• ISSNs: 0173-0835

Abstract

Abstract : As populations age, the number of patients sustaining traumatic brain injury (TBI) and concomitantly receiving preinjury antiplatelet therapy such as aspirin (ASA) and clopidogrel (CLOP) is rising. These drugs have been linked with unfavorable clinical outcomes following TBI, where the exact mechanism(s) involved are still unknown. In this novel work, we aimed to identify and compare the altered proteome profile imposed by ASA and CLOP when administered alone or in combination, prior to experimental TBI. Furthermore, we assessed differential glycosylation PTM patterns following experimental controlled cortical impact model of TBI, ASA, CLOP, and ASA + CLOP. Ipsilateral cortical brain tissues were harvested 48 h postinjury and were analyzed using an advanced neuroproteomics LC‐MS/MS platform to assess proteomic and glycoproteins alterations. Of interest, differential proteins pertaining to each group (22 in TBI, 41 in TBI + ASA, 44 in TBI + CLOP, and 34 in TBI + ASA + CLOP) were revealed. Advanced bioinformatics/systems biology and clustering analyses were performed to evaluate biological networks and protein interaction maps illustrating molecular pathways involved in the experimental conditions. Results have indicated that proteins involved in neuroprotective cellular pathways were upregulated in the ASA and CLOP groups when given separately. However, ASA + CLOP administration revealed enrichment in biological pathways relevant to inflammation and proinjury mechanisms. Moreover, results showed differential upregulation of glycoproteins levels in the sialylated N‐glycans PTMs that can be implicated in pathological changes. Omics data obtained have provided molecular insights of the underlying mechanisms that can be translated into clinical bedside settings.